Bicycle Therapeutics banks a $52M B round for the next leg of the long R&D journey ahead
A trans-Atlantic biotech with one foot in Cambridge, UK and another planted in Cambridge, MA has raised close to $52 million as it looks to beef up its staff and steer a range of its uniquely designed drug conjugates into the clinic.
Bicycle Therapeutics won backing from a long list of marquee investors: Vertex Ventures led the round with help from new investors Cambridge Innovation Capital and Christophe Westphal’s Longwood Fund. Bicycle’s existing investors – Novartis Venture Fund, GlaxoSmithKline’s SROne, SVLS and Atlas Venture — all came back for the B round.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
